Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris

Status Terminated

Clinical Trial Summary

Ultra-violet light B (UVB) therapy has been used by dermatologists to treat psoriasis for decades. Only a few studies have begun to dissect the mechanism of how NB-UVB therapy causes lesion resolution. Results from this study will aid in identifying other diseases that may be treated successfully with NB-UVB. If we can identify the mechanism of action of this therapy, this may give us additional new therapeutic targets for psoriasis and other diseases. Our overall hypothesis is that UVB induces changes that will indicate a mechanism of action of this therapy in psoriasis.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00844363
Study type	Interventional
Source	Rockefeller University
Contact
Status	Terminated
Phase	N/A
Start date	November 2008
Completion date	May 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03598790` - A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis	Phase 3
Completed	`NCT00799877` - Chronic Plaque Psoriasis (Ps) Registry
Completed	`NCT02581345` - Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis	Phase 3
Withdrawn	`NCT01200264` - Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy	Phase 2
Terminated	`NCT00972543` - Raptiva in Palm and Sole Psoriasis	Phase 4
Not yet recruiting	`NCT00707070` - Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis	Phase 4
Completed	`NCT00539929` - Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis	Phase 2
Completed	`NCT02852967` - A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis	Phase 2
Completed	`NCT00770965` - Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis	Phase 2
Active, not recruiting	`NCT06011733` - A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis	Phase 3
Completed	`NCT00245765` - Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy	Phase 2
Completed	`NCT00673556` - A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate	Phase 3
Completed	`NCT00574249` - Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment	Phase 3
Completed	`NCT00512187` - Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial	Phase 4
Completed	`NCT02570750` - The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis
Completed	`NCT00438360` - Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis	Phase 3
Active, not recruiting	`NCT03897075` - Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis	Phase 3
Completed	`NCT01358578` - Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis	Phase 3
Completed	`NCT03536884` - A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis	Phase 3
Completed	`NCT03230292` - A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis	Phase 2